For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 117,665 | |||
| General and administrative | 48,644 | |||
| Total operating expenses | 166,309 | |||
| Loss from operations | -166,309 | |||
| Interest income | 10,960 | |||
| Interest expense | 5,482 | |||
| Foreign exchange loss, net | -131 | |||
| Change in fair value of 2022 usd financing warrants | 22,831 | |||
| Gain on extinguishment of contribution payable | 0 | |||
| Total other expense, net | -17,484 | |||
| Net loss | -183,793 | |||
| Unrealized gain on investments | 330 | |||
| Gain/(loss) on foreign currency translation | -64 | |||
| Comprehensive loss | -183,527 | |||
| Earnings per share, basic, total | -2.06 | |||
| Earnings per share, diluted, total | -2.06 | |||
| Weighted average number of shares outstanding, basic, total | 89,327,608 | |||
| Weighted average number of shares outstanding, diluted, total | 89,327,608 | |||
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)